Morepen Laboratories Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹746 Cr +81.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
ML

Morepen Laboratories Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Morepen Laboratories Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹466Cr
+10.2% YoY
+2.9% QoQ
Net profit
₹20Cr
−31% YoY
−25.9% QoQ
Margin
9%
−2 pp YoY
+1 pp QoQ

What the Q4 FY25 call signalled

1 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Order bookOrder book flat
Price₹96
Market cap₹4.2K Cr
P/E35.9

The short version

The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27.

From Morepen Laboratories Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27.
  • Finished dosage business has shown a 21% growth in 2 years, with expectations of higher growth than API segment.
  • API business growth has been muted (~3-4%), but capacity expansion from 314 KL to 600 KL by FY '26 is expected to boost revenues.
  • Export focus is increasing, with export revenues growing 26% over 3 years; export now constitutes 72% of business.
  • Medical devices segment is expanding capacity significantly (e.g., BP monitors capacity doubling from 9 to 18 lakh units) and expected to deliver strong growth given health awareness trends.
  • The new molecule contribution in API is rising, forecasting faster growth in this segment.

2 more points from Morepen Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Morepen Laboratories is completing the expansion of API manufacturing capacity from 314 KL to 600 KL, nearly doubling capacity, expected to be completed within FY '26.
  • After the 600 KL capacity expansion, there are no immediate plans for further capacity increases.
  • The company is exploring partnerships with outsourcing vendors who have surplus capacity or complementary product mixes.
  • Investment is ongoing in backward integration, especially in the medical devices segment, aiming to increase EBITDA margins.

2 more points from Morepen Laboratories Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book flat
  • The company has 600 KL capacity planned for FY '26, expected to be completed within the year.
  • Current installed capacity is 514 KL as part of capacity expansion (91% increase targeted).
  • They are working on building a good outsourcing partner network to manage excess demand or capacity shortage.
  • Despite a recent price drop of 24%, quantity sold has increased by 57% in APIs, indicating robust order intake.
  • Some export orders (US and Europe) were deferred last quarter, impacting short-term revenues.
  • Management is in a "wait and watch" mode regarding price acceptance by Indian customers due to recent raw material price increases and global market conditions.

2 more points from Morepen Laboratories Ltd's call on order book

Create a free account to keep reading this call

Morepen Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Morepen Laboratories Ltd Q4 FY25 results — key figures

Morepen Laboratories Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue466423+10.2%453+2.9%
Operating profit (EBITDA)4248-12.5%36+16.7%
Operating margin9%11%-2 pp8%+1 pp
Profit before tax2642-38.1%35-25.7%
Net profit (PAT)2029-31%27-25.9%
EPS (₹)0.370.55-32.7%0.49-24.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Morepen Laboratories Ltd Q4 FY25 results?

The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27.

What is Morepen Laboratories Ltd share price analysis?

Morepen Laboratories Ltd currently shows a below-average growth signal. The stock trades at a P/E of 35.9 with a market cap of ₹4,216 Cr. Investors should review the full earnings analysis for detailed insights.

Is Morepen Laboratories Ltd planning capital expenditure?

Morepen Laboratories is completing the expansion of API manufacturing capacity from 314 KL to 600 KL, nearly doubling capacity, expected to be completed within FY '26. - After the 600 KL capacity expansion, there are no immediate plans for further capacity increases. - The company is exploring partnerships with outsourcing vendors who have surplus capacity or complementary product mixes. - Investment is ongoing in backward integration, especially in the medical devices segment, aiming to increase EBITDA margins. - There is focus on expanding formulations and OTC products, including hiring new teams and launching products in new markets like the U.S.

Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.